[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Martin Blomberg Jensen\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":94},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,71],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100636918","phase-1-a-novel-aromatase-inhibitor-leflutrozole-for-treatment-of-non-obstructive-azoospermia-100636918",false,"NCT07571928","A Novel Aromatase Inhibitor, Leflutrozole, for Treatment of Non-Obstructive Azoospermia","The NOVA-NOA Trial A Novel Aromatase Inhibitor, Leflutrozole, for Treatment of Non-Obstructive Azoospermia A Prospective Interventional Study","NOVA-NOA","Inclusion Criteria:\n\n* Signed informed consent by participant\n* Signed informed consent by participant's partner (must just be obtained before the par-ticipant starts treatment at Visit 1), if applicable, regarding blood samples, data collec-tion about fertility treatment as well as pregnancy and pregnancy outcome\n* 18-55 years\n* Azoospermia verified by at least 2 semen samples, average semen volume \\>= 1,0 ml with no identifiable sign of obstruction (samples taken at Visit -1 and at Visit 0 prior to confirmation of eligibility and dosing).\n* Serum AMH or Inhibin B level above the lower limit of quantification (LLOQ) at screening or within 6 months prior to screening\n* Testosterone \\\u003C 15 nmol\u002FL at screening or within 6 months prior to screening\n* Serum estradiol above the lower limit of normal range (48 pmol\u002FL) at screening or within 6 months prior to screening\n\nExclusion Criteria:\n\n* Klinefelter or other major genetic conditions including large deletions on sex chromosomes\n* Average testis size \\> 20 mL unless obstruction has been excluded\n* TESE procedure \\\u003C ½ year ago\n* LH concentration \\> 15 IU\u002FL at screening\n* Current abuse of steroids\n* BMI \\> 45 kg\u002Fm2\n* Severe chronic diseases requiring daily medication\n* Prior thromboembolic event within the last 24 months\n* Cardiovascular event within the last 6 months judged as significant by the investigator\n* Osteoporosis requiring medical treatment\n* Use of any prescription or non-prescription medication (apart from routine vitamins, occasional use of paracetamol, acetylsalicylic acid, or ibuprofen) which could interfere with pharmacokinetic or pharmacodynamic results, as judged by the investigator, such as:\n\n  * Herbal products and non-routine vitamins\n  * Insulin\n  * Medication such as systemic corticosteroids, tricyclic antidepressants, and atypical antipsychotics\n* Surgery scheduled for the trial duration period, except for minor, non-gastrointestinal surgical procedures at the discretion of the investigator\n* Cancer (past or present, except basal cell skin cancer or squamous cell skin cancer), which in the investigator's opinion could interfere with the results of the trial\n* Serum prostate specific antigen (PSA) \\> 3 ng\u002FmL at screening or within 6 months prior to screening\n* Hematocrit \\>50% at screening or within 6 months prior to screening\n* Mental incapacity, language barriers or unwillingness to comply with the requirements of the protocol, which may preclude adequate understanding or co-operation during the trial, as judged by the investigator","MALE","18 Years","55 Years",{"count":21,"type":22},15,"ESTIMATED","INTERVENTIONAL",[25,26],"PHASE1","PHASE2","This clinical interventional study aims to assess whether treatment with with leflutrozole can improve sperm production in infertile men with non-obstructive azoospermia selected by serum anti-mullerian hormone (AMH) or Inhibin B as a positive predictive biomarker.",[29,30],"Infertility Due to Azoospermia","Infertility, Male","NOT_YET_RECRUITING","2026-04-30",{"date":34,"type":35},"2026-05-06","ACTUAL",{"date":37,"type":22},"2026-05-01",{"date":39,"type":22},"2027-08-31",{"name":41,"class":42},"Martin Blomberg Jensen","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":52,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":43},"100612503","phase-2-compass---copenhagen-menopause-study-100612503","NCT07254429","COMPASS - COpenhagen MenoPAuSe Study","Copenhagen Menopause Study (COMPASS): A Randomized Clinical Trial","COMPASS","Inclusion Criteria:\n\n* Women \\>40 years and ≤65 at screening visit\n* A body mass index between 18-35\n* Confirmed menopause\n\n  * Method 1\n  * Spontaneous amenorrhea for ≥12 consecutive months\n  * Negative urine hCG test\n  * Method 2\n  * Spontaneous amenorrhea for ≥6 months\n  * FSH \\>30 mIU\u002FL\n  * Negative urine hCG test\n* Moderate to severe vasomotor symptoms (VMS)\n\n  * Within the 7 days prior to randomization, participants must report ≥ 14 moderate to severe VMS per week\n\nExclusion Criteria:\n\n* Current or previous hormone replacement therapy (HRT)\n\n  * Vaginal estradiol\u002Fvaginal inserts (e.g. Vagifem®) can be used, but will have to be pause 2 weeks prior to randomization and throughout the study period\n  * Menopausal Hormone Therapy (MHT) can be used by participants, but must be paused 6 weeks prior to inclusion.\n* Current or previous cancer diagnosis\n\n  * Except for basal cell carcinoma\n* Known BRCA gene mutation\n* Current hyperthyroid disease\n* Osteoporosis\n* Major psychiatric diagnosis including ongoing medication e.g. selective serotonin re-uptake inhibitors (SSRIs)\n* Known prolonged QT or other known clinically significant abnormal ECG, including taking medication that can prolong QT interval (e.g. sotalol, dronedarone, amiodarone, methadone, and several antipsychotic drugs)\n* Previous myocardial infarction or heart failure\n* Previous thromboembolic event\n* The use of opioids, anticoagulating treatment or unwilling to pause fish oil\u002FOmega-3 supplements 3 days prior visit 1 and 3\n* Current alcohol or drug abuse\n* Hypertension treated with more than two drugs\n* Severe history of allergy, hypersensitivity, or intolerance to drugs\n* Moderate to severe liver and kidney disease (eGFR \\\u003C60 mL\u002Fmin)\n* Diagnosed with type 1 or 2 diabetes\n* Chronic diseases requiring immunomodulatory treatments such as rheumatoid arthritis, inflammatory bowel disease, and vasculitis etc.\n* Known uterine fibroids, Endometriosis, Systemic lupus erythematosus (SLE), otosclerosis, severe migraine or sleep apnea\n* Known Epilepsy or previous seizures or convulsive disorder","FEMALE","40 Years","65 Years",{"count":56,"type":22},192,[26],"During menopause, estrogen levels drop while the level of another hormone - LH (luteinizing hormone) substantially increases. This hormonal shift is linked to bone Loss and other complications. Estrogen therapy can help, but some women avoid it due to the increased risk of blood clots and cancer. This project will investigate whether blocking LH could offer a safe alternative to alleviate symptoms and complications of menopause since it is known from previous research that high LH levels contribute to both bone deterioration and metabolic issues. The goal is to explore new treatment options that can improve health and quality of life for women both during and after menopause. This randomized clinical trial is a single center, sponsor-investigator-initiated single-blinded 8 weeks clinical trial with four parallel groups comparing the effect of an gonadotropin releasing hormone(GnRH)-analog with placebo, and with two additional arms given estrogen or testosterone on change on bone health in postmenopausal women with moderate-to-severe symptoms.",[60,61],"Menopausal Osteoporosis","Bone Markers","RECRUITING","2026-02-27",{"date":65,"type":35},"2026-03-02",{"date":67,"type":35},"2025-10-02",{"date":69,"type":22},"2028-05",{"name":41,"class":42},{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":81,"phases":4,"briefSummary":82,"conditions":83,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":43},"100384944","hypercalcemia-after-paraffin-oil-injection-100384944","NCT04292288","Hypercalcemia After Paraffin Oil Injection","Hypercalcemia After Paraffin Oil Injection: Aetiology, Pathogenesis and Possible Treatment Options","Inclusion Criteria: - previous injection of paraffin oil into the body\n\n\\-\n\nExclusion Criteria: - inability to walk\n\n* inability to understand the consequences of inclusion\n* incurable cancer disease","80 Years",{"count":80,"type":22},200,"OBSERVATIONAL","Today, there is an increased use of non-medical, invasive cosmetic treatments globally without sufficient awareness of possible health risks. A particular problem is young men injecting large amounts of paraffin oil into skeletal muscles especially on upper arms and chest to increase the visible size of the muscles. Several case reports have suggested that intramuscular injection of paraffin oil induces foreign body reaction and granuloma formation and subsequently hypercalcemia. Our hypothesis is that increased generation of activated vitamin D (1,25(OH)2D3) in the marcrophages may be responsible for the persistent hypercalcemia. Now trhe investigators want to include a large group of men who injected 100-10.000 ml paraffin oil to identify risk factors for developing hypercalcemia and try to understand the pathogenesis of the disease. Additionally, granuloma tissue from selected patients will be cultured ex vivo to investigate whether they produce 1,25(OH)2D3 or PTHrP and to test which drugs can most effectively be used to lower calcium levels in these men. Subsequently, we will try to stratify the men according to the severity of the changes in calcium homeostasis as we suggest that this stratification will be the basis for future intervention trials",[84,85],"Hypercalcemia","Granuloma","2025-04-02",{"date":88,"type":35},"2025-04-06",{"date":90,"type":35},"2019-04-01",{"date":92,"type":22},"2029-01-01",{"name":41,"class":42},""]